Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals strong financial performance with increased royalty revenue and improved coverage approval rates, suggesting growing market confidence. The Q&A section supports this with positive feedback on guideline changes and future growth strategies. Despite flat U.S. revenues, the company has initiatives to drive future growth. The anticipated profitability by Q1 2026, coupled with the strong ESC guidelines reception, further supports a positive outlook. However, the lack of guidance for 2026 introduces some uncertainty, preventing a 'Strong positive' rating.
Key Financial Performance
Total Revenue $87.3 million, an increase of 69% year-over-year. The growth was driven by strong U.S. performance, increased prescription growth, and collaboration revenue.
U.S. Net Product Revenue $40.7 million, an increase of 31% year-over-year. Growth attributed to nearly double-digit sequential quarterly prescription growth and enhanced patient access programs.
Collaboration Revenue $46.7 million, an increase of approximately 128% year-over-year. Growth driven by increases in royalty sales within partner territories and product sales to collaboration partners.
Research and Development Expenses $14.1 million, an increase of 36% year-over-year. The increase was primarily due to higher costs associated with ongoing development projects.
Selling, General and Administrative Expenses $41.8 million, an increase of 5% year-over-year. The increase was primarily related to higher legal costs associated with ANDA litigation and increased media costs.
Medicare Coverage Approval Rate 87% average approval rate with out-of-pocket costs reduced to $29 for a 30-day supply compared to $64 in Q1 2025. The improvement reflects growing payer confidence and enhanced patient access.
Commercial Coverage Approval Rate 86% average approval rate with out-of-pocket costs reduced to $36 for a 30-day supply compared to $55 in Q1 2025. The improvement reflects growing payer confidence and enhanced patient access.
Royalty Revenue from Daiichi Sankyo Europe $16.4 million, an increase of 21% sequentially from Q2 2025. Growth attributed to robust revenue growth and expanded market share in Europe.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Bempedoic acid products: Achieved inclusion in the ESC/EAS guidelines as a Class 1 Level A recommendation, validating its clinical impact for statin-intolerant patients. Anticipated inclusion in U.S. guidelines in early 2026.
ESP-2001: Nominated as the first preclinical development candidate for primary sclerosing cholangitis (PSC). IND-enabling studies to begin with a goal to file an IND with the FDA in 2026.
U.S. Market: Outpaced the broader adjunct lipid-lowering market, delivering growth exceeding all other non-statin products. Launched targeted campaigns for statin-intolerant patients and expanded direct-to-consumer initiatives.
International Market: Daiichi Sankyo Europe expanded market share and geographic reach in Europe. Otsuka Pharmaceutical received marketing approval for NEXLETOL in Japan, with favorable pricing approval expected to drive significant milestone payments. Progress in Canada, Israel, and Australia/New Zealand for market approvals.
Revenue Growth: Total revenue grew 69% year-over-year to $87.3 million. U.S. net product revenue increased 31% year-over-year to $40.7 million.
Cost Reductions: Achieved significant reductions in out-of-pocket costs for Medicare and commercial coverage, improving patient access and prescription fulfillment rates.
Generic Agreements: Finalized agreements with four generic manufacturers to delay generic versions of NEXLETOL and NEXLIZET until April 2040.
Vision 2040: Preparing to introduce Vision 2040, focusing on long-term growth and shareholder value.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Legal Costs: Increased legal costs associated with ANDA litigation were noted, which could impact financials and operational focus.
Market Access Investments: Near-term investments in enhanced patient access programs and Medicare coverage required significant costs, which could strain financial resources in the short term.
Supply Chain and Manufacturing: Ongoing technology transfer processes for manufacturing with partners like DSE could pose risks of delays or disruptions.
Economic and Pricing Pressures: Efforts to reduce out-of-pocket costs for patients and improve payer coverage may pressure margins and profitability.
Competitive Pressures: The company faces competition from other non-statin lipid-lowering products, which could impact market share and growth.
Strategic Execution Risks: The success of new marketing campaigns and international expansion efforts depends on effective execution, which carries inherent risks.
Pipeline Development: The development of new candidates like ESP-2001 for PSC involves preclinical and clinical risks, including potential delays or failures.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Esperion anticipates sustained revenue growth driven by strategic marketing initiatives, expanded payer coverage, and international partnerships. The company expects the inclusion of bempedoic acid in U.S. guidelines in Q1 2026 to further boost growth.
Market Expansion: Esperion is preparing for expanded market reach with the inclusion of bempedoic acid in U.S. guidelines and ongoing international launches in regions like Japan, Canada, Israel, and Australia. These efforts are expected to generate significant milestone payments and royalty streams.
Product Development: The company plans to file an IND with the FDA in 2026 for ESP-2001, a preclinical candidate for primary sclerosing cholangitis, aiming to initiate first-in-human clinical studies.
Operational Investments: Esperion is increasing investments in patient support programs, market access contracts, and direct-to-consumer initiatives to leverage upcoming growth opportunities.
Financial Guidance: Esperion reiterates its full-year 2025 operating expense guidance of $215 million to $235 million, including $15 million in noncash expenses related to stock compensation.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What were the drivers behind the gross margins for this quarter, and how can we expect this to progress moving forward?
A:The gross margin drivers were consistent with previous quarters, primarily due to low-margin tablet sales to partners. The company emphasized the importance of tech transfer and moving manufacturing off their books, which is expected to complete by the end of the year and early next year. Gross margins are expected to improve over the course of 2026, aligning more closely with typical pharmaceutical companies.
Q:Can you comment on achieving sustainable profitability in Q1 of 2026 and whether this includes any incoming milestones?
A:The company does not include milestones when discussing profitability. They are confident in achieving sustainable profitability, as they are tracking in line with their forecast. Nonrecurring expenses in Q3 affected net income but are not expected to repeat, supporting their outlook for profitability.
Q:Why were U.S. revenues flat despite a 9% quarter-over-quarter increase in scripts, and what does this mean for reimbursement moving forward?
A:U.S. revenues were flat due to onetime investments with Medicare plans for preferred access and the introduction of a new e-voucher for 90-count prescriptions. These initiatives aim to reduce patient abandonment and set the stage for future growth. The company is already seeing a 30% increase in gross sales in Q4 compared to the same time last quarter.
Q:What feedback has been received from the ESC guideline changes, and how might this impact the U.S. market?
A:The ESC guideline changes have been positively received, with strong enthusiasm from physicians and key opinion leaders in Europe. The guidelines position bempedoic acid as a foundational therapy based on compelling data from the CLEAR Outcomes study. This is expected to positively influence U.S. guidelines, anticipated in early Q1, and drive growth.
Q:What are the next steps for Otsuka in Japan following preliminary pricing, and when is the launch expected?
A:Otsuka is awaiting final pricing, which is expected within 2-3 weeks. The launch will occur shortly after final pricing approval. The company is optimistic about the Japanese market, the third-largest lipid market globally, and plans to support the launch.
Q:What is the current utilization of 340B for NEXLETOL and NEXLIZET, and how might this evolve in 2026?
A:340B utilization is minimal and has no significant impact on the company's outlook or revenues. It is not a factor in their operations.
Q:What is the status of the pipeline and PSC, including IND filing and enrollment timing?
A:The company is in the planning phase for PSC, including discussions with the FDA on endpoints and other requirements. They are moving quickly due to the unmet need and aim to provide updates as plans progress. The drug ESP-2001 is highlighted for its potential to treat symptoms and repair injury, potentially reducing the need for liver transplants.
Q:What is the split between specialists and primary care physicians in the prescriber base, and is this changing?
A:The prescriber base is stable, with 60% primary care physicians and 40% cardiologists. This aligns with historical trends and the company's expectations. Primary care physicians are particularly responsive to messaging on primary prevention and statin intolerance.
Q:What is the progress on the DSE manufacturing process, and will there be guidance for 2026?
A:The DSE manufacturing process is progressing well, with ramp-up expected early next year. Gross margins are expected to improve significantly over 2026. The company has not yet decided on providing guidance for 2026.
Q:What factors are driving confidence in continued prescription momentum despite the January deductible reset?
A:The company cites strong reimbursement, effective messaging, and positive feedback from physicians as key drivers of prescription momentum. The ESC guidelines and anticipated U.S. guidelines are also expected to support growth into the new year.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding whether they will issue guidance for 2026, stating only that they are still discussing it internally.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chief Commercial
Commercial Officer
Disney
EAS guideline
ESC EAS
ESP
Health
Hulu
IND
NEXLETOL NEXLIZET
NILEMDO
TV
approval rate
award
blockbuster franchise
candidate
care professional
commercial
coverage pocket
day supply
engagement
equity offering
groundwork
health care
hypercholesterolemia
inclusion guideline
increase prescription
industry
lipid
marketing campaign
milestone payment
month
pricing approval
reach
recognition
sic
treatment
use
ESPR Transcript
Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript
Positive3-10
The earnings call reveals strong financial performance with significant revenue growth, a positive outlook with expected benefits from new guidelines, and strategic market expansion. The Q&A session shows confidence in overcoming competitive risks and highlights potential gains from the triple combination therapy. Although management was vague about some timelines, the overall sentiment, driven by strong revenue, optimistic guidance, and market expansion, suggests a positive stock price movement.
Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-20
Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call summary reveals strong financial performance with increased royalty revenue and improved coverage approval rates, suggesting growing market confidence. The Q&A section supports this with positive feedback on guideline changes and future growth strategies. Despite flat U.S. revenues, the company has initiatives to drive future growth. The anticipated profitability by Q1 2026, coupled with the strong ESC guidelines reception, further supports a positive outlook. However, the lack of guidance for 2026 introduces some uncertainty, preventing a 'Strong positive' rating.
ESPR Slides
ESPR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
